Hypophosphatasia The U.S. Soft Bones Foundation Revenue and Competitors

Boonton, NJ USA

Location

N/A

Total Funding

Health

Industry

Estimated Revenue & Valuation

  • Hypophosphatasia The U.S. Soft Bones Foundation's estimated annual revenue is currently $3.1M per year.(i)
  • Hypophosphatasia The U.S. Soft Bones Foundation's estimated revenue per employee is $162,000

Employee Data

  • Hypophosphatasia The U.S. Soft Bones Foundation has 19 Employees.(i)
  • Hypophosphatasia The U.S. Soft Bones Foundation grew their employee count by 19% last year.

Hypophosphatasia The U.S. Soft Bones Foundation's People

NameTitleEmail/Phone
1
Executive DirectorReveal Email/Phone
2
Communications Manager and Patient/Caregiver NavigatorReveal Email/Phone
3
Patient Liaison and advocateReveal Email/Phone
4
Region LeadReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8.2M38-7%N/AN/A
#2
$9.5M4413%N/AN/A
#3
$12.9M5310%N/AN/A
#4
$7.8M363%N/AN/A
#5
$54.9M1857%N/AN/A
#6
$14.1M584%N/AN/A
#7
$8.4M398%N/AN/A
#8
$30.5M11310%N/AN/A
#9
$9.7M45-10%N/AN/A
#10
$4.2M22-8%N/AN/A
Add Company

What Is Hypophosphatasia The U.S. Soft Bones Foundation?

The mission of Soft Bones Foundation is to provide valuable information, education and support for people living with hypophosphatasia (HPP), their families and caregivers. The Foundation will also promote research of this rare bone disease through awareness and fund-raising efforts. Hypophosphatasia is an inherited metabolic (chemical) bone disease that results from low levels of an enzyme called alkaline phosphatase (ALP). Enzymes are proteins that act in the body's chemical reactions by breaking down other chemicals. ALP is normally present in large amounts in bone and liver. In hypophosphatasia, abnormalities in the gene that makes ALP lead to production of inactive ALP. Subsequently, several chemicals - including phosphoethanolamine, pyridoxal 5'-phosphate (a form of vitamin B6) and inorganic pyrophosphate - accumulate in the body and are found in large amounts in the blood and urine of people with Hypophosphatasia. It appears that the accumulation of inorganic pyrophosphate is the cause of the characteristic defective calcification of bones in infants and children (rickets) and in adults (osteomalacia). As yet, there is no cure for hypophosphatasia and no proven medical therapy. Some medications are being evaluated. Treatment is generally directed towards preventing or correcting the symptoms or complications.

keywords:N/A

N/A

Total Funding

19

Number of Employees

$3.1M

Revenue (est)

19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.8M19-10%N/A
#2
$4.3M250%N/A
#3
$1.7M30-36%N/A
#4
$6.3M31-31%N/A
#5
$3.5M34-13%N/A